Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Expenses: 2012-2024

Historic Operating Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $168.4 million.

  • Amphastar Pharmaceuticals' Operating Expenses rose 66.79% to $78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year increase of 23.13%. This contributed to the annual value of $168.4 million for FY2024, which is 9.28% up from last year.
  • Amphastar Pharmaceuticals' Operating Expenses amounted to $168.4 million in FY2024, which was up 9.28% from $154.1 million recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Expenses peaked at $168.4 million during FY2024, and registered a low of $129.9 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $154.1 million (2023), whereas its average is $154.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Operating Expenses dropped by 1.91% in 2021, and later grew by 9.28% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Expenses (Yearly) stood at $132.4 million in 2020, then fell by 1.91% to $129.9 million in 2021, then grew by 8.86% to $141.4 million in 2022, then increased by 9.03% to $154.1 million in 2023, then grew by 9.28% to $168.4 million in 2024.